Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans

Biochemical Pharmacology

Volumn 76, Issue 12, 2008, Pages 1757-1764

  Li, Cheng ^a   Liu, Tongtong ^a   Broske, Lisa ^a   Brisson, Jean Marc ^a   Uss, Annette S ^a   Njoroge, F George ^a   Morrison, Richard A ^a   Cheng, K C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HCV protease inhibitor; Human pharmacokinetics prediction; In vivo and in vitro pharmacokinetics

Indexed keywords

CILUPREVIR; CYCLOSPORIN A; GLYCOPROTEIN P; PROTEINASE INHIBITOR; TELAPREVIR;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; TIGHT JUNCTION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HEPACIVIRUS; HUMANS; LIVER; P-GLYCOPROTEIN; PEPTIDES; PERMEABILITY; PROTEASE INHIBITORS; RATS; TIGHT JUNCTIONS;

EID: 56749177102     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.005     Document Type: Article

References (20)

1. Reed K.E., and Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242 (2000) 55-84
2. Sarazzin C., Rouzier R., Wagner F., Forwstier N., Larrey D., Gupta K.S., et al. SCH 503034, a novel hepatitis C virus inhibitor, plus pegylated interferon α-2b for genotype 1 nonreesponders. Gastroenterology 132 (2007) 1270-1278
3. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
4. Resnick HW, Zeuzem S, van Vliet A, McNair L, Purdy S, Chu H-M, Jansen PL. Dig Dis Week, May 14-19, 2005, Chicago, IL, Abs #527.
5. Burton P.S., Conradi R.A., Ho N.F.H., Hilgers A.R., and Borchardt R.T. How structural features influence the biomembrane permeability of peptides. J Pharm Sci 85 (1996) 1336-1340
6. Liederer B.M., Fuchs T., Vander Velde D., Siahaan T.J., and Borchardt R.T. Effects of amino acid chirality and the chemical linker on the cell permeability characteristics of cyclic prodrugs of opioid peptides. J Med Chem 49 (2006) 1261-1270
7. Li C., Wainhaus S., Uss A.S., and Cheng K.-C. High-throughput screening using Caco-2 and PAMPA systems. In: Kim K.-J., and Ehrhardt C. (Eds). Preclinical Biopharmaceutics - in situ, in vitro and in silico tools for drug absorption studies (2008), Springer 418-429
8. Cheng K.-C., Li C., and Uss A.G. Prediction of oral drug absorption in humans - from cultured cell lines and from experimental animals. Expert Opin Drug Metab Tox 4 (2008) 481-490
9. Cheng K.-C., Korfmacher W.A., White R.E., and Njoroge F.G. Lead optimization in discovery drug metabolism and pharmacokinetics: case study- the hepatitis C virus protease inhibitor SCH 503034. Persp Med Chem 1 (2007) 1-9
10. Chiou W.L., and Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15 (1998) 1792-1795
11. Li C., Nair L., Li F., Liu T., Pichardo J., Agrawal S., et al. Correlation between PAMPA permeability and cellular activities of HCV protease inhibitors. Biochem Pharm 75 (2008) 1186-1197
12. Knipp G.T., Vander Velde D.G., Siahaan T.J., and Borchardt R.T. The effect of β-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers. Pharm Res 14 (1997) 1332-1340
13. Gangmar S., Jois S.D.S., Siahaan T.J., Vander Velde D.G., Stella V.J., and Borchardt R.T. The effect of conformation on membrane permeability of an acyloxlalkoxy-linked cyclic prodrug of a model hexapeptide. Pharm Res 13 (1996) 1657-1662
14. Borchardt R.T. Optimizing oral absorption of prptide using prodrug strategies. J Control Release 62 (1996) 231-238
15. Pauletti G.M., Okumu F.W., and Borchardt R.T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayer via the paracellular pathway. Pharm Res 14 (1997) 164-168
16. Knipp G.T., Ho N.F.H., Barsuhn C.L., and Borchadrt R.T. Paracellular diffusion in Caco-2 cell monolayer: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 86 (1997) 1105-1110
17. Walter E., and Kissel T. Transport of peptidomimetic renin inhibitors across monolayers of a human intestinal cell line (Caco-2): evidence for self-enhancement of paracellular transport route. J Pharm Sci 3 (1995) 215-230
18. Walker D.K., Abel S., Comby P., Muirhead G.J., Nedderman A.N., and Smith D.A. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33 (2005) 587-595
19. Beaumont K., Harper A., Smith D.A., and Bennett J. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. Eur J Pharm Sci 12 (2000) 41-50
20. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15 (1998) 11-22